Kiora Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company. It involved in developing and commercializing products for treating ophthalmic diseases. The company's product pipeline includes KIO-301, KIO-101 and KIO-201. Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals Inc., is based in SALT LAKE CITY.
| Revenue (Most Recent Fiscal Year) | $16.02M |
| Net Income (Most Recent Fiscal Year) | $-10.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.85 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -59.30% |
| Return on Assets (Trailing 12 Months) | -41.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.71 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 4.43M |
| Free Float | 4.43M |
| Market Capitalization | $11.88M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | -0.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.05% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.97% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |